MIST vs. ANIX, PRPH, ONCY, ACRS, SPRO, ETON, CLSD, CMRX, QTTB, and BRNS
Should you be buying Milestone Pharmaceuticals stock or one of its competitors? The main competitors of Milestone Pharmaceuticals include Anixa Biosciences (ANIX), ProPhase Labs (PRPH), Oncolytics Biotech (ONCY), Aclaris Therapeutics (ACRS), Spero Therapeutics (SPRO), Eton Pharmaceuticals (ETON), Clearside Biomedical (CLSD), Chimerix (CMRX), Q32 Bio (QTTB), and Barinthus Biotherapeutics (BRNS). These companies are all part of the "pharmaceutical preparations" industry.
Milestone Pharmaceuticals (NASDAQ:MIST) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations, community ranking and institutional ownership.
Anixa Biosciences has lower revenue, but higher earnings than Milestone Pharmaceuticals. Anixa Biosciences is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Milestone Pharmaceuticals has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, Anixa Biosciences has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.
86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are owned by institutional investors. 10.4% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 22.6% of Anixa Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Anixa Biosciences had 1 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 2 mentions for Anixa Biosciences and 1 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 1.61 beat Anixa Biosciences' score of 0.00 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media.
Anixa Biosciences' return on equity of -44.09% beat Milestone Pharmaceuticals' return on equity.
Milestone Pharmaceuticals currently has a consensus price target of $10.75, suggesting a potential upside of 521.39%. Anixa Biosciences has a consensus price target of $12.00, suggesting a potential upside of 302.68%. Given Milestone Pharmaceuticals' higher possible upside, equities analysts clearly believe Milestone Pharmaceuticals is more favorable than Anixa Biosciences.
Milestone Pharmaceuticals received 57 more outperform votes than Anixa Biosciences when rated by MarketBeat users. Likewise, 67.57% of users gave Milestone Pharmaceuticals an outperform vote while only 64.29% of users gave Anixa Biosciences an outperform vote.
Summary
Milestone Pharmaceuticals beats Anixa Biosciences on 9 of the 17 factors compared between the two stocks.
Get Milestone Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MIST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Milestone Pharmaceuticals Competitors List
Related Companies and Tools
